XBiotech Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESS Newswire / January 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or […]

Innovative Industrial Properties, Inc. Sued for Securities Law Violations – Contact Levi & Korsinsky Before March 18, 2025 to Discuss Your Rights – IIPR

NEW YORK, NY / ACCESS Newswire / January 26, 2025 / If you suffered a loss on your Innovative Industrial Properties, Inc. (NYSE:IIPR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/innovative-industrial-properties-inc-lawsuit-submission-form?prid=125162&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com

Sun Communities, Inc. Sued for Securities Law Violations – Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights – SUI

NEW YORK, NY / ACCESS Newswire / January 26, 2025 / If you suffered a loss on your Sun Communities, Inc. (NYSE:SUI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sun-communities-inc-lawsuit-submission-form?prid=125158&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Aehr Test Systems, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – AEHR

NEW YORK, NY / ACCESSWIRE / January 26, 2025 / If you suffered a loss on your Aehr Test Systems, Inc. (NASDAQ:AEHR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/aehr-lawsuit-submission-form?prid=125154&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors – Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / January 26, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=125152&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Levi & Korsinsky Reminds JinkoSolar Holding Co., Ltd. Investors of the Ongoing Investigation into Potential Violations of Securities Laws – JKS

NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of JinkoSolar Holding Co., Ltd. ("JinkoSolar Holding Co., Ltd.") (NYSE:JKS) concerning possible violations of federal securities laws. JinkoSolar issued a press release on January 17, 2025, reporting "estimates for certain preliminary unaudited financial

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of MGP Ingredients, Inc.(MGPI) Shareholders

NEW YORK, NY / ACCESS Newswire / January 26, 2025 / If you suffered a loss on your MGP Ingredients, Inc. (NASDAQ:MGPI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/mgp-ingredients-inc-lawsuit-submission-form?prid=125148&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Shareholder Rights Advocates at Levi & Korsinsky Investigate Intellia Therapeutics, Inc. (NTLA) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".

Scroll to Top